Clinical Trial Update: A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of AB-201 for HER2-positive solid tumors has been withdrawn, with the study status updated to withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AB-201

Snippet

Sponsor: Artiva Biotherapeutics, Inc. | Conditions: Breast Cancer, Gastric Cancer | Phase 1, Phase 2 | Status: WITHDRAWN